


Axinn Obtains Stipulated Summary Judgment of Non-Infringement for Zydus

NEWS | LESS THAN 1 MIN READ

January 20, 2016

Axinn successfully obtained a stipulated order of non-infringement regarding a patent asserted against its client, Zydus, in ongoing patent litigation concerning generic versions of Abilify® (aripiprazole). Otsuka markets Abilify® and had filed an amended complaint adding infringement allegations related to U.S. Patent No. 8,759,350, which the Court dismissed without prejudice. Otsuka then filed a second amended complaint against Zydus adding the '350 patent. Before Zydus answered the second amended complaint, the Court construed the claims of the '350 patent favorably for Zydus. In light of this favorable claim construction, Axinn succeeded in negotiating a stipulated summary judgment of non-infringement concerning the '350 patent.

Related People



Jason Murata

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- American Bar Association 2025 Asia-Pacific Conference
SPEAKING ENGAGEMENT ANTITRUST
- NBA Commercial Law Section 38th Annual Corporate Counsel Conference
SPONSORSHIP ANTITRUST
- GCR Live: Law Leaders Global 2025
SPEAKING ENGAGEMENT ANTITRUST
- The 32nd Annual Marketing Partner Forum
EVENT
- SABA North America Corporate Counsel Retreat 2025
SPONSORSHIP ANTITRUST
- Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2025
CLIENT ALERTS ANTITRUST
- Four Axinn Thought Leadership Pieces Nominated for the Antitrust Writing Awards
AWARDS & RECOGNITIONS ANTITRUST
- Merger Remedies Back in Vogue Under Trump
MEDIA MENTIONS ANTITRUST
- Three Takeaways from the Initial Determination at the ITC Regarding Standard Essential Patents in the 1380 Investigation
AXINN VIEWPOINTS INTELLECTUAL PROPERTY

- A POSA's Motivation Is Not Required To Be the Same as the Inventor's in Evaluating Obviousness

AXINN VIEWPOINTS INTELLECTUAL PROPERTY

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved